Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › IXHL

Incannex Healthcare

IXHL Lead: Phase 2 ★ Read the deep dive → 10 Biotech Distilled articles ↓ 32 filings & releases ↓ Cash $67.7M (Jun 30, 2026) ↓ 10 verdicts ↓
NeurologyRespiratory Small Molecule

Market cap $28.1M 12.5M shares (10-K, Sep 24, 2026) × $2.24 close Nov 6, 2026

Most recent annual filing: 2026-09-25

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. PSX-001 Ph2b start2026PSX-001 Ph2b start, 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

Discontinued (1)

Capital (as filed)

Cash
$67.7M cash and cash equivalents · Jun 30, 2026 (10-K)
Operating cash flow
−$3.2M annual ÷ 4, year to Jun 30, 2026 (10-K)
As stated in coverage
$70.0M cash per the update of Jun 25, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (10)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (10 calls)

Every verdict Biotech Distilled has published on Incannex Healthcare, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-01-11 Watch Incannex (IXHL): Scientific Deep Dive for IHL-42X and Pipeline Products Incannex has plausible science and adequate cash but faces competitive pressure from Apnimed and GLP-1s; wait for FDA Phase 3 meeting minutes before committing capital.
  2. 2026-02-14 Watch UPDATE: Incannex (IXHL) - Q2 Fiscal 2026 Update Nothing in the Q2 10-Q changes the core thesis; the valuation rests entirely on the H1 2026 FDA meeting for IHL-42X, so staying on the sidelines is warranted.
  3. 2026-02-28 Watch UPDATE: Incannex (IXHL) - The Predicted Reverse Split Arrives... The 1-for-30 reverse split is mechanical Nasdaq compliance engineering; the entire thesis still hinges on the H1 2026 FDA meeting, so staying on the sidelines remains appropriate.
  4. 2026-03-14 Avoid UPDATE: Incannex (IXHL) - The Goalposts Move, The Dilution Hits, and Phase 3 is Delayed to 2027 Phase 3 delayed to 2H 2027, a dilutive $10M RDO with 100% warrant coverage was issued despite $69M cash on hand, and the near-term binary catalyst is gone — thesis is broken.
  5. 2026-03-21 Avoid UPDATE: Incannex (IXHL) - Damage Control, Negative Enterprise Value, and the Reality of Biotech Markets Management's negative-enterprise-value complaint and buyback paradox reflect financial engineering rather than scientific progress; the 18-month Phase 3 delay makes this dead money.
  6. 2026-03-28 Avoid UPDATE: Incannex (IXHL) - Buying Goodwill and Baffling Buybacks Management is financially engineering a price floor via contradictory buybacks and AASM sponsorship rather than advancing clinical science; the broken thesis is unchanged.
  7. 2026-04-27 Avoid UPDATE: Incannex (IXHL) - The White House Throws Psychedelics a Bone, and IXHL Grabs the Microphone The White House EO is a class-level psychedelic tailwind that doesn't fix the broken IHL-42X timeline, toxic capital structure, or Incannex's second-tier positioning in psilocybin.
  8. 2026-05-15 Avoid UPDATE: Incannex (IXHL) - DReAMzz Officially Starts. The Clock on Dead Money Begins. DReAMzz commencing is necessary execution but not a re-rating event; the 18-month dead-money window, warrant overhang, and dilution bazooka remain fully intact.
  9. 2026-06-25 Avoid UPDATE: Incannex (IXHL) - One of the Four BUY Triggers Just Fired. The Other Three Didn't. A US patent on IHL-42X is a genuine IP de-risking but only one of the four required BUY triggers has fired; the 18-month Phase 3 delay, warrant overhang, and capital structure problems remain.
  10. 2026-08-25 Avoid UPDATE: Incannex (IXHL) - First Patient Dosed. The Checkpoint I Named Just Cleared. First patient dosed in DReAMzz is real operational progress but doesn't move the 2H 2027 Phase 3 wall, resolve the warrant overhang, or fire a second BUY trigger.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (32)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 22, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)